Labcorp to Deploy FDA‑Cleared AISight Dx Nationwide

Labcorp says it has expanded its collaboration with PathAI to deploy AISight Dx nationwide across Labcorp’s anatomic pathology laboratories and hospital collaborations as an enterprise digital pathology rollout. The release frames the effort as a way to bring digital slide workflows and AI-enabled image analysis into routine anatomic pathology operations at scale.

In describing day-to-day use, the announcement says the platform enables pathologists to view and manage slides digitally. Labcorp also characterizes the deployment as supporting fully digital workflows spanning case management and slide review, with collaboration and annotation features intended to facilitate review and communication across its network and hospital partnerships. Overall, the rollout is presented as an organization-wide move toward end-to-end digital pathology workflows across its anatomic pathology footprint.

For enterprise deployment, the release describes AISight Dx as a cloud-based digital pathology platform for viewing and managing slides. Labcorp describes the infrastructure as incorporating secure storage and system connectivity, and it lists workflow features such as case management and collaboration. The announcement also describes an AI component, stating that pathologists can use AI to support key steps in the diagnostic process and that the platform integrates AI-powered image analysis, without presenting clinical performance claims. In that framing, AISight Dx is portrayed as a digital-and-AI layer for handling slides, cases, and associated analysis in a single environment.

Regulatory positioning is described as a core part of the announcement, with AISight Dx presented as FDA-cleared for primary diagnosis in the United States. The release also states the platform is CE‑IVD marked for primary diagnosis in the European Economic Area, the United Kingdom, and Switzerland.

Labcorp frames the expanded collaboration as part of a longer-running relationship, stating that the current deployment builds on its 2019 strategic investment in PathAI. It also says the platform will incorporate digital pathology workflows in support of its precision medicine products, positioning the initiative within its broader diagnostics and pathology services portfolio.

The announcement closes by depicting the nationwide rollout as both a partnership expansion and an infrastructure build-out intended to support digital pathology and AI-enabled workflows over time.

Key Takeaways:

• Labcorp’s press release describes a nationwide deployment of AISight Dx across its anatomic pathology laboratories and hospital collaborations as an enterprise digital pathology rollout.
• The release highlights cloud-based deployment, secure storage, system connectivity, and workflow functions such as digital slide viewing/management, case management, collaboration, annotation, and AI-powered image analysis to support steps in the diagnostic process.
• Regulatory status is described as FDA clearance for primary diagnosis in the US and CE‑IVD marking for primary diagnosis in the EEA, UK, and Switzerland, and the collaboration is framed as an expansion building on Labcorp’s 2019 strategic investment in PathAI.